CD44 and neoplasm: In order to better characterize these two cell populations, an additional FACs panel including a tumor marker (EpCAM), stem cell markers (CD44, CD24, and CD133) and mesenchymal‐like and mesothelial cell markers (CD90, podoplanin and mesothelin) was established.